Company intelligence / Profile preview

Ichnos Sciences Inc.

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Ichnos Sciences has three clinical-stage oncology assets under investigation, with ISB 2001 (BCMA x CD38 x CD3 trispecific antibody) currently in Phase 1 trials for relapsed/refractory multiple myeloma. Two of their molecules have received orphan drug designation from the U.S. FDA.

Therapeutic areas: OncologyImmunologyHematology
Modalities: BiologicsMultispecific antibodiesSmall molecules
Industry: Biotech

Partnerships

Glenmark Pharmaceuticals Ltd.

Beyond the preview

Go deeper on Ichnos Sciences Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ichnos Sciences Inc..